Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius Medical Care AG & Co. KGaA    FME   DE0005785802

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Xetra
11/25/2020 11/26/2020 11/27/2020 11/30/2020 12/01/2020 Date
69.94(c) 70.24(c) 70.82(c) 70.5(c) 70.76(c) Last
516 117 333 404 437 779 968 739 435 789 Volume
-0.48% +0.43% +0.83% -0.45% +0.37% Change
More quotes
Financials (USD)
Sales 2020 21 231 M - -
Net income 2020 1 532 M - -
Net Debt 2020 15 175 M - -
P/E ratio 2020 16,5x
Yield 2020 1,63%
Sales 2021 22 153 M - -
Net income 2021 1 654 M - -
Net Debt 2021 13 705 M - -
P/E ratio 2021 15,2x
Yield 2021 1,73%
Capitalization 25 013 M 24 977 M -
EV / Sales 2020 1,89x
EV / Sales 2021 1,75x
Nbr of Employees 126 463
Free-Float 65,1%
More Financials
Company
Fresenius Medical Care AG & Co. KGaA is the world's leading supplier of services and equipment for patients with kidney problems. Net sales break down by activity as follows: - clinical care services (79.4%): operated, at the end of 2019, 3,994 institutions; - manufacturing of dialyzers and related products (20.6%): hemo-dialysis and pediatric dialysis machines, etc. The group also offers therapies accompanied by... 
More about the company
Notations Surperformance© of Fresenius Medical Care AG & Co. KGaA
Trading Rating : Investor Rating :
More Ratings
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
11/30FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 41 of the Wp..
EQ
11/27Swiss drugmaker Vifor had bid interest but talks halted - sources
RE
11/24FRESENIUS SE : UBS remains Neutral
MD
11/19FMC FRESENIUS MEDICAL CARE AG & CO K : RBC reiterates its Neutral rating
MD
11/19FMC FRESENIUS MEDICAL CARE AG & CO K : Bernstein reiterates its Neutral rating
MD
11/19FRESENIUS SE : Bernstein reiterates its Buy rating
MD
11/17FMC FRESENIUS MEDICAL CARE AG & CO K : Jefferies reiterates its Neutral rating
MD
11/16FRESENIUS MEDICAL CARE : included for 11th time in Dow Jones Sustainability Inde..
PU
11/13FRESENIUS SE : Receives a Buy rating from Bernstein
MD
11/12FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Neutral rating from Bernstein
MD
11/11FRESENIUS MEDICAL CARE AG & CO. KGAA : Notification and public disclosure of tra..
EQ
11/09Switzerland's Vifor strikes kidney drug deal with Angion
RE
11/06FRESENIUS SE : Kepler Cheuvreux gives a Buy rating
MD
11/05FMC FRESENIUS MEDICAL CARE AG & CO K : UBS maintains a Buy rating
MD
11/04FMC FRESENIUS MEDICAL CARE AG & CO K : Gets a Buy rating from Goldman Sachs
MD
More news
News in other languages on FRESENIUS MEDICAL CARE AG & CO. KGAA
11/30DGAP-NVR : Fresenius Medical Care AG & Co. KGaA: Veröffentlichung der Gesamtzahl..
11/27INSIDER : Vifor Pharma hat Übernahme-Interessenten angelockt
11/27Morning Briefing International
11/26Asklepios leidet unter Corona-Krise - deutlich weniger Patienten
11/26DZ Bank senkt fairen Wert für Fresenius SE - 'Kaufen'
More news
Analyst Recommendations on FRESENIUS MEDICAL CARE AG & CO. KGAA
More recommendations
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | FME | DE0005785802 | MarketScreener
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 95,34 $
Last Close Price 85,42 $
Spread / Highest target 31,2%
Spread / Average Target 11,6%
Spread / Lowest Target -25,6%
EPS Revisions
Managers
NameTitle
Rice Powell Chairman-Management Board
Dieter Schenk Chairman-Supervisory Board
Helen Giza Chief Financial Officer
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer